Mannitol Fresenius

Mannitol, the active ingredient in Mannitol Fresenius, is an osmotic diuretic presented as an injection solution for intravenous use. It reduces intracranial pressure, promotes diuresis in acute renal failure, and helps eliminate renal toxins. GNH USA supplies Mannitol Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Mannitol is an osmotic agent used in clinical settings to manage fluid balance and pressure‑related conditions. - Reduction of intracranial pressure: lowers cerebral edema and intracranial pressure in traumatic brain injury or postoperative neurosurgical patients. - Promotion of diuresis in acute renal failure: increases urine output to aid renal clearance when kidney function is compromised. - Facilitation of renal excretion of toxins: enhances elimination of nephrotoxic substances such as contrast media or certain drugs.

Mannitol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate discomfort often reported after infusion. - Nausea or vomiting: gastrointestinal upset during or shortly after administration. - Electrolyte imbalance: especially hyponatremia or hyperkalemia. - Thirst or dry mouth: sensation of increased plasma osmolality. - Tachycardia: transient increase in heart rate. - Hypotension: due to rapid plasma volume shifts.

Serious or Rare Side Effects: - Pulmonary edema: fluid accumulation in lungs, particularly in patients with cardiac dysfunction. - Severe hyponatremia: marked drop in serum sodium requiring urgent correction. - Acute renal failure: paradoxical worsening of kidney function in susceptible individuals. - Anaphylactic reaction: rare hypersensitivity with rash, bronchospasm, or shock. - Hemolysis: especially in patients with G6PD deficiency. - Metabolic acidosis: significant acid‑base disturbance.

Mannitol should be used with careful clinical monitoring. - Renal function: assess baseline creatinine and urine output before initiation. - Electrolyte status: monitor serum sodium, potassium, and osmolality during therapy. - Cardiovascular status: watch for signs of fluid overload or hypotension. - Pregnancy: consider only when benefits outweigh potential risks, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol may interact with other agents that affect fluid, electrolyte, or blood pressure balance.

Major Interactions (Avoid): - Loop diuretics: additive diuretic effect can precipitate severe dehydration or electrolyte loss. - Insulin: may potentiate hypoglycemia due to rapid shifts in plasma volume.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: enhanced hypotensive response may require dose adjustment. - Nephrotoxic agents (e.g., aminoglycosides, contrast media): increased risk of renal injury. - Lithium: altered renal clearance may raise lithium levels, necessitating monitoring.